Loading
A phase 1/2 trial of Capmatinib and Amivantamab in non-small-cell lung cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.
A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT05488314 by Janssen Research & Development, LLC, with 57 participants enrolled, started 2022-12-13 and due to reach its primary completion in 2027-04-28. Interventions recorded: Capmatinib and Amivantamab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Non-small-cell lung cancer and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Small-molecule kinase inhibitors and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Non-small-cell lung cancer and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Small-molecule kinase inhibitors and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Small-molecule kinase inhibitors and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Small-molecule kinase inhibitors and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/